✨ Free AI Report
Syros Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Syros Pharmaceuticals, Inc.
Company Research

Syros Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Syros Pharmaceuticals, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Biotech company at critical inflection point following failed flagship trial and planned Nasdaq delisting, facing significant execution risk despite innovative gene control platform. The Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve its primary endpoint of complete response rate. Syros plans to voluntarily delist its common stock from.

What is Syros Pharmaceuticals, Inc.'s industry? Syros Pharmaceuticals, Inc. (syros.com) operates in Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics. AskCyborg classifies Syros Pharmaceuticals, Inc. under Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics in its company registry.

Syros Pharmaceuticals is a biopharmaceutical company focused on the development of treatment for hematologic malignancies. The company operates within the biopharmaceutical sector, focusing on the development of treat...

3/ 10Challenged

Cyborg Score thesis

Biotech company at critical inflection point following failed flagship trial and planned Nasdaq delisting, facing significant...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Syros Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Syros Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Syros Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Syros Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Syros Pharmaceuticals, Inc. Overview

Pro stress-test →

Syros Pharmaceuticals is a biopharmaceutical company focused on the development of treatment for hematologic malignancies. The company operates within the biopharmaceutical sector, focusing on the development of treatments that control the expression of genes to address the root causes of diseases, leveraging its proprietary gene control platform to design therapies for cancer and monogenic diseases.

Strategic Profile

Pro stress-test →

Lead product candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III clinical trial for myelodysplastic syndrome and Phase II for acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I clinical trial. The company is navigating significant development challenges following recent clinical trial setbacks.

Competitive Landscape

Pro stress-test →

Syros competes in the hematologic malignancy and gene control therapeutic space against large pharma and other biotech companies. The company's gene control platform represents a differentiated approach, but recent clinical failures have undermined competitive positioning. Key competitors include larger oncology-focused pharmaceutical companies with more established development pipelines and financial resources.

Industry Context

Syros Pharmaceuticals, Inc. operates in Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics.

Key facts

Founded: 2011 · Headquarters: Cambridge, Massachusetts · Revenue: $0.39M · Market cap: $0.68M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Syros Pharmaceuticals, Inc..

  • Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve primary endpoint - major setback for lead program
  • Company plans voluntary delisting from Nasdaq and deregistration - signals reduced transparency and financial stress
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2024SELECT-MDS-1 Phase 3 trial failure - Tamibarotene did not meet primary endpoint
  • 2024Announced planned voluntary delisting from Nasdaq
  • +2 moreTrack every material event for Syros Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Syros Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Oncology ProgramsEstablished cancer therapeutic portfolio→Hematologic Malignancy TreatmentsMarket leader in multiple myeloma and related conditions→Gene-Targeted TherapeuticsGene control and editing platform company→

Compare Syros Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Syros Pharmaceuticals, Inc. operates in Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics research →
NEW · MCP server

Ask your AI assistant about Syros Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Syros Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Syros Pharmaceuticals, Inc. do this quarter?”
“Is Syros Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Syros Pharmaceuticals, Inc. do?+
Syros Pharmaceuticals is a biopharmaceutical company focused on the development of treatment for hematologic malignancies. The company operates within the biopharmaceutical sector, focusing on the development of treat...
What is Syros Pharmaceuticals, Inc.'s Cyborg Score?+
Syros Pharmaceuticals, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Syros Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Oncology Programs, Hematologic Malignancy Treatments, Gene-Targeted Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Syros Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Syros Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Syros Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

3Syros Pharmaceuticals, Inc.